Adapsyn is developing a bioinformatics platform devoted to discovering previously unidentified natural product drug candidates.
Adapsyn Bioscience is a owner and operator of a biotechnology company intended to focus on the identification and characterization of microorganism-derived small molecules, to uncover chemical agents possessing novel biological activities relevant to the biotechnology and pharmaceutical sectors. The company's services is supported by cutting-edge bioinformatic software platforms and state of the art laboratory facilities, enabling researchers to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better protect users from a wide spectrum of diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 11, 2018 | Series Unknown | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Pfizer R&D Innovate | — | Series Unknown |